ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis

Detalles Bibliográficos
Autores principales: Burkbauer, Laura, Goldbach, Macy M., Tchou, Julia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
ASO Author Reflections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310403/
https://www.ncbi.nlm.nih.gov/pubmed/34304315
http://dx.doi.org/10.1245/s10434-021-10517-w
_version_ 1783728753803788288
author Burkbauer, Laura
Goldbach, Macy M.
Tchou, Julia C.
author_facet Burkbauer, Laura
Goldbach, Macy M.
Tchou, Julia C.
author_sort Burkbauer, Laura
collection PubMed
description
format Online
Article
Text
id pubmed-8310403
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83104032021-07-26 ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis Burkbauer, Laura Goldbach, Macy M. Tchou, Julia C. Ann Surg Oncol ASO Author Reflections Springer International Publishing 2021-07-24 2021 /pmc/articles/PMC8310403/ /pubmed/34304315 http://dx.doi.org/10.1245/s10434-021-10517-w Text en © Society of Surgical Oncology 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle ASO Author Reflections
Burkbauer, Laura
Goldbach, Macy M.
Tchou, Julia C.
ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
title ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
title_full ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
title_fullStr ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
title_full_unstemmed ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
title_short ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
title_sort aso author reflections: objective response rate after short duration (< 9 weeks) is not inferior to moderate (9–27 weeks) or long duration (> 27 weeks) of neoadjuvant endocrine therapy (net)—an ncdb analysis
topic ASO Author Reflections
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310403/
https://www.ncbi.nlm.nih.gov/pubmed/34304315
http://dx.doi.org/10.1245/s10434-021-10517-w
work_keys_str_mv AT burkbauerlaura asoauthorreflectionsobjectiveresponserateaftershortduration9weeksisnotinferiortomoderate927weeksorlongduration27weeksofneoadjuvantendocrinetherapynetanncdbanalysis
AT goldbachmacym asoauthorreflectionsobjectiveresponserateaftershortduration9weeksisnotinferiortomoderate927weeksorlongduration27weeksofneoadjuvantendocrinetherapynetanncdbanalysis
AT tchoujuliac asoauthorreflectionsobjectiveresponserateaftershortduration9weeksisnotinferiortomoderate927weeksorlongduration27weeksofneoadjuvantendocrinetherapynetanncdbanalysis

Ejemplares similares